Big trial failure for Xarelto in clot prevention won’t affect sales, Bayer vows
admin 6th October 2017 Uncategorised 0When Bayer said late yesterday that it stopped a trial of Xarelto in the secondary prevention of stroke and embolism for lack of efficacy, analysts would have been forgiven for taking an ax to their estimates for the $3.4 billion-a-year drug, which Bayer markets in partnership with Johnson & Johnson. Not so fast, Bayer says.
More: Big trial failure for Xarelto in clot prevention won’t affect sales, Bayer vows
Source: fierce